Sugi Predict

Sugi Predict / Compounds / SCHEMBL2640314

SCHEMBL2640314

SCHEMBL2640314

O=[N+]([O-])c1cccc(CNc2cccn3nc(Cl)nc23)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 4/20 0.66
▸ PTK2 Q05397 4/20 0.66
▸ JAK3 P52333 2/20 0.66
▸ MAPT P10636 4/20 0.51
▸ MEN1 O00255 3/20 0.51
▸ KMT2A Q03164 3/20 0.51
▸ KCNN3 Q9UGI6 1/20 0.50
▸ ALDH1A1 P00352 3/20 0.49
▸ TDO2 P48775 2/20 0.44
▸ IDO1 P14902 1/20 0.44
▸ MET P08581 1/20 0.44
▸ PDE5A O76074 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ CRHBP P24387 1/20 0.43
▸ CRHR2 Q13324 1/20 0.43
▸ EGFR P00533 2/20 0.43
▸ IGF1R P08069 2/20 0.43
▸ TSHR P16473 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2640419 0.80 JAK2 (1.00) JAK2PTK2JAK3MAPTMEN1
SCHEMBL2640386 0.80 JAK2 (1.00) JAK2PTK2JAK3MAPTMEN1
SCHEMBL2640439 0.80 JAK2 (0.66) JAK2PTK2JAK3MAPTMEN1
SCHEMBL2640558 0.78 JAK2 (0.59) JAK2PTK2JAK3
SCHEMBL2640444 0.74 PTK2 (0.61) JAK2PTK2JAK3
SCHEMBL2640491 0.74 JAK2 (0.60) JAK2PTK2JAK3MAPTMEN1
SCHEMBL2640461 0.73 JAK2 (0.50) JAK2PTK2JAK3ALDH1A1
SCHEMBL2640290 0.73 JAK2 (0.56) JAK2PTK2MEN1KMT2APOLB
SCHEMBL13285571 0.72 MAPT (0.57) MAPTMEN1KMT2AKCNN3ALDH1A1
SCHEMBL17201936 0.70 EGFR (0.53) MAPTMEN1KMT2AKCNN3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633173-B2 Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives CEPHALON, INC (US) 2014-01-21 — — US disclosed
US-20130296312-A1 Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives CEPHALON, INC. 2013-11-07 — — US disclosed
US-8501936-B2 Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives CEPHALON, INC. (US) 2013-08-06 — — US disclosed
EP-2438066-A2 PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a]PYRIDINE DERIVATIVES Cephalon, Inc. (US) 2012-04-11 — — EP disclosed
US-20100311693-A1 Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives CEPHALON, INC. (US) 2010-12-09 — — US disclosed
WO-2010141796-A2 PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES CEPHALON, INC. (US) 2010-12-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130296312-A1 Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives JAK2, JAK1, JAK3 JAK2 1/4885PTK2 451/4885JAK3 3/4885
US-20100311693-A1 Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives CCNA1, CCNY, RB1 JAK2 31/4885PTK2 1114/4885JAK3 175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.